Johnson & Johnson (JNJ) Deferred Taxes (2009 - 2026)
Johnson & Johnson (JNJ) posted Deferred Taxes of -$479.0 million for Q2 2026, down 401.26% sequentially from $159.0 million in Q1 2026, and down 158.06% YoY from $825.0 million in Q2 2025.
Johnson & Johnson (JNJ) Deferred Taxes (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Deferred Taxes for 18 years, with the latest figure at -$479.0 million in Q2 2026.
- Quarterly Deferred Taxes fell 158.06% year-over-year to -$479.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.8 billion (down 157.93% YoY) and the FY2025 annual result came in at $1.5 billion, up 170.45% from the prior year.
- Deferred Taxes fell to -$479.0 million in Q2 2026 per JNJ's latest filing, from $159.0 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $2.2 billion in Q3 2025 and troughed at -$3.7 billion in Q4 2025.
- A 5-year average of -$324.0 million and a median of -$247.5 million in 2024 frame the typical range for Deferred Taxes.
- The widest YoY moves for Deferred Taxes: up 2364.44% in 2025, down 22881.25% in 2025.
- Over 5 years, Deferred Taxes stood at -$926.0 million in 2022, then sank by 160.48% to -$2.4 billion in 2023, then soared by 99.34% to -$16.0 million in 2024, then slumped by 22881.25% to -$3.7 billion in 2025, then surged by 86.97% to -$479.0 million in 2026.
- According to Business Quant data, Deferred Taxes over the past three periods registered -$479.0 million, $159.0 million, and -$3.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -291.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -587.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -1.32 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -479.00 Mn |
| Mar 29, 2026 | 159.00 Mn |
| Dec 28, 2025 | -3.68 Bn |
| Sep 28, 2025 | 2.22 Bn |
| Jun 29, 2025 | 825.00 Mn |
| Mar 30, 2025 | 2.17 Bn |
| Dec 29, 2024 | -16.00 Mn |
| Sep 29, 2024 | 90.00 Mn |
| Jun 30, 2024 | -695.00 Mn |
| Mar 31, 2024 | -1.56 Bn |
| Dec 31, 2023 | -2.41 Bn |
| Oct 1, 2023 | 560.00 Mn |
| Jul 2, 2023 | -799.00 Mn |
| Apr 2, 2023 | -1.54 Bn |
| Jan 1, 2023 | 901.00 Mn |
| Apr 3, 2022 | -926.00 Mn |
| Oct 3, 2021 | -1.88 Bn |
| Jul 4, 2021 | 45.00 Mn |
| Apr 4, 2021 | -730.00 Mn |
| Jan 3, 2021 | -903.00 Mn |